30mg vial with 3ml bac water included
Quanta Pharma Retatrutide 30 mg is a triple agonist peptide acting on GLP-1, GIP, and glucagon receptors. It is studied for its integrated effects on insulin regulation, energy balance, and appetite control, with research interest in its potential impact on weight and metabolic outcomes.
Research focus includes:
Triple receptor activity — engages GLP-1, GIP, and glucagon signalling pathways in metabolic research
Metabolic regulation — investigated for effects on glucose control and insulin sensitivity
Energy expenditure — explored for its role in increasing metabolic activity and lipid utilisation
Appetite modulation — studied for effects on hunger signalling and satiety mechanisms
Pharmacokinetics — characterised by an extended half-life supporting once-weekly research protocols
